dc.contributor.author | Kelly, RS | |
dc.contributor.author | Patnick, J | |
dc.contributor.author | Kitchener, HC | |
dc.contributor.author | Moss, SM | |
dc.contributor.author | Grp, NHSCSPHPVSI | |
dc.date.accessioned | 2018-08-13T11:07:32Z | |
dc.date.issued | 2011-09-27 | |
dc.identifier | 7 | |
dc.identifier.citation | BRITISH JOURNAL OF CANCER, 2011, 105 pp. 983 - 988 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2320 | |
dc.identifier.doi | 10.1038/bjc.2011.326 | |
dc.description.abstract | BACKGROUND: Earlier pilot studies of human papillomavirus (HPV) triage concluded that HPV triage was feasible and cost-effective. The aim of the present study was to study the impact of wider rollout of HPV triage for women with low-grade cytology on colposcopy referral and outcomes. METHODS: Human papillomavirus testing of liquid-based cytology (LBC) samples showing low-grade abnormalities was used to select women for colposcopy referral at six sites in England. Samples from 10 051 women aged 25-64 years with routine call or recall cytology reported as borderline or mild dyskaryosis were included. RESULTS: Human papillomavirus-positive rates were 53.7% in women with borderline cytology and 83.9% in those with mild dyskaryosis. The range between sites was 34.8-73.3% for borderline cytology, and 73.4-91.6% for mild dyskaryosis. In the single site using both LBC technologies there was no difference in rates between the two technologies. The positive predictive value of an HPV test was 16.3% for CIN2 or worse and 6.1% for CIN3 or worse, although there was considerable variation between sites. CONCLUSION: Triaging women with borderline cytological abnormalities and mild dyskaryosis with HPV testing would allow approximately a third of these women to be returned immediately to routine recall, and for a substantial proportion to be referred for colposcopy without repeat cytology. Variation in HPV-positive rates results in differing colposcopy workload. British Journal of Cancer (2011) 105, 983-988. doi:10.1038/bjc.2011.326 www.bjcancer.com Published online 6 September 2011 (C) 2011 Cancer Research UK | |
dc.format.extent | 983 - 988 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | NATURE PUBLISHING GROUP | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1038/bjc.2011.326 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2011-09-27 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | BRITISH JOURNAL OF CANCER | |
pubs.notes | affiliation: Moss, SM (Reprint Author), Inst Canc Res, Canc Screening Evaluat Unit, Richard Doll Bldg,15 Cotswold Rd, Sutton SM2 5NG, Surrey, England. Kelly, R. S.; Moss, S. M., Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England. Patnick, J., NHS Canc Screening Programmes, Sheffield, S Yorkshire, England. Kitchener, H. C., Univ Manchester, Sch Canc Studies & Enabling Sci, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England. keywords: cervical cytology; screening; human papillomavirus; triage keywords-plus: HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; ARTISTIC TRIAL; WOMEN; CANCER; SMEARS; ABNORMALITIES; METAANALYSIS; MANAGEMENT research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] funding-acknowledgement: Manchester Biomedical Research Centre; NHS Cancer Screening Programmes funding-text: Professor HC Kitchener was supported by the Manchester Biomedical Research Centre. All authors have completed the Unified Competing Interest form at https://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author), and declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and, no other relationships or activities that could appear to have influenced the submitted work. The Cancer Screening Evaluation Unit received funding from the NHS Cancer Screening Programmes to carry out this evaluation. The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or nonexclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd. and its licensees to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sub-licences to exploit all subsidiary rights, as set out in our licence (https://resources.bmj.com/bmj/authors/checklists-forms/licence-for-publi cation). number-of-cited-references: 17 times-cited: 50 usage-count-last-180-days: 0 usage-count-since-2013: 3 journal-iso: Br. J. Cancer doc-delivery-number: 826MI unique-id: ISI:000295357900017 oa: gold_or_bronze da: 2018-08-13 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH) | |
pubs.volume | 105 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Cancer Screening Evaluation Unit (DoH) | en_US |
dc.contributor.icrauthor | Moss, Susan Mary | |